Jeff has more than twenty years of life sciences experience, having served in lead business and legal roles in both public and private companies. As CEO of EXACT Sciences Corp. (NASDAQ: EXAS), Jeff led its turnaround and recapitalization through a strategic transaction with Genzyme Corp., putting the company on a strong footing for growth. As a founder of SynapDx Corp. Mr. Luber joined Stan Lapidus, serial entrepreneur and founder of Cytyc Corporation, to develop the first-ever blood-based diagnostic for autism spectrum disorder. Mr. Luber currently leads the corporate development effort for Good Start Genetics and also serves as the company’s general counsel. Mr. Luber has also held board of director seats with EXACT Sciences Corp. and with the Accelerated Cure Project for MS. He received his BS in Business Administration from Southern Connecticut State University and his JD and MBA from Suffolk University.
Greg is an expert developer of genome analysis technology and has served as a Lecturer on Genetics at Harvard Medical School as well as the Personal Genome Project Director of Technology. During that time, he co-developed the Polonator, a high-throughput commercial DNA sequencing system, in collaboration with Danaher Motion Dover. Greg also co-developed one of the first next-generation DNA sequencing systems at Harvard, which was further developed by Applied Biosystems to become the SOLiD platform. He is a featured author in numerous prestigious publications, an inventor on multiple patents/applications for nucleic acid analysis and has consulted for sequencing-related biotech companies. Greg is a Founder of Good Start Genetics. He holds a PhD in Genetics from Harvard University and a BS in computer science and biology from The College of New Jersey.
Marc Jones has served as Good Start Genetics’ chief financial officer since January 2016 and brings nearly 20 years of corporate finance and strategy experience from both public and private companies. Previously, Marc served as chief financial officer of T2 Biosystems (NASDAQ: TTOO), a company focused on developing innovative diagnostic products to improve patient health. With T2 Biosystems he raised nearly $100 million in capital, including the initial public offering. Prior to joining T2 Biosystems, Marc also served as chief financial officer of Crashlytics, a fast growing mobile device software company, until its acquisition by Twitter. Marc was chief financial officer of Ivenix, a medical technology company developing a next-generation infusion management system, where he led all finance, administrative and operations functions, and was also chief financial officer of CHiL Semiconductor until its acquisition. Previously, Marc held a number of other corporate finance positions ranging from Fortune 50 companies, such as Lockheed Martin, to dot-com startups, such as iBasis, Inc. Marc holds an M.S. in finance from Northeastern University and a B.S. in economics and finance from Southern New Hampshire University.
Jim Frontero has more than 25 years experience developing sales and commercial operations with medical and consumer brand companies. He has established a track record of success in every organization and brings a passion and enthusiasm to everything he does. Prior to GoodStart, Jim served as SVP Sales and Commercial Operations at Devicor Medical, a privately owned global leader in minimally invasive and vacuum assisted breast biopsy. At Devicor Jim helped to reverse a declining US business to 12% growth and successful divestment. Previously, Jim was President of Straumann USA, a global leader in implant dentistry, and prior to Straumann Jim spent 14 years at Boston Scientific in various roles of sales and commercial leadership. Jim holds a BS in Business Administration from Cornell University and received his MBA from Boston University.
Lori brings to the company more than 25 years of commercialization experience in the healthcare industry. Prior to joining Good Start Genetics, Lori served as the Vice President of Sales for EMD Serono Reproductive Health where she led the division to market leadership of their flagship fertility product. Lori also served as Vice President of Sales and Marketing for MDR Pharmaceuticals, a national pharmacy specializing in the distribution of fertility medications for reproductive health, and Senior Director of Global Commercial Development for Javelin Pharmaceuticals until its acquisition by Hospira, Inc., where she prepared the company and the market for the launch of 3 brands. Lori spent 9 years at Novartis holding various positions in sales, sales leadership, managed care, operations, and management development. She started her career in research in the human genetics lab at UMDNJ. She holds a bachelor’s degree in biology from the College of St. Elizabeth in Convent Station, New Jersey.
Nicole has more than twenty years of life sciences experience working in broad range of molecular and clinical diagnostics. Before joining Good Start in 2012, Nicole spent over a decade at Genzyme Genetics/Integrated Genetics/Lab Corp. Her responsibilities included clinical case sign out, research and development of molecular oncology assays, process development of clinical resulting and reporting systems, and integration of labs added to Genzyme Genetics.
Nicole earned her Ph.D. in Biomedical Sciences from the University of Massachusetts Medical School. She completed her Medical Genetics Fellowship at Harvard Medical School training in Boston Children’s Hospital for pediatric disease, Dana Farber Pathology for oncology genetics, Mass General Hospital for neurogenetics, The Brigham and Women’s Hospital for genetic counseling and inherited genetic diseases, and Genzyme Genetics for clinical molecular testing.
She is a diplomat of the American Board of Medical Genetics, holding certification in Clinical Molecular Genetics, and is a Fellow of the American College of Medical Genetics. She is NYS certified in both Molecular Genetic testing and Molecular Oncology.
Mark Umbarger has over 13 years of experience developing cutting-edge genomic analysis methodologies, including next generation sequencing (NGS) technologies. In George Church’s lab at Harvard Medical School, Mark developed experimental and computational tools to understand the three-dimensional structure of genomes and worked extensively on the polony sequencing system, one of the first NGS technologies.
Following his PhD, Mark brought his experience to Good Start Genetics (GSG) where he developed the company’s NGS-based carrier screening assay, a test that has been run in GSG’s CLIA and CAP approved lab since 2011. Mark now leads the Research and Development team at GSG and is responsible for the building of GSG’s new product portfolio.
Mark is an author of four issued patents, has published in prominent scientific journals such as Molecular Cell and Genetics in Medicine, and frequently presents at scientific conferences and meetings in the reproductive health space. Mark holds a PhD in Genetics from Harvard University and a BA in Chemistry and Molecular Biology and Biochemistry (with honors) from Wesleyan University.
Jeffrey R. Luber has more than twenty years of life sciences experience, having served in lead business and legal roles in both public and private companies.
As CEO of EXACT Sciences Corp. (NASDAQ: EXAS), Jeff led its turnaround and recapitalization through a strategic transaction with Genzyme Corp., putting the company on a strong footing for growth. As a founder of SynapDx Corp. Mr. Luber joined Stan Lapidus, serial entrepreneur and founder of Cytyc Corporation, to develop the first-ever blood-based diagnostic for autism spectrum disorder.
Mr. Luber currently leads the corporate development effort for Good Start Genetics and also serves as the company’s general counsel. Mr. Luber has also held board of director seats with EXACT Sciences Corp. and with the Accelerated Cure Project for MS.
He received his BS in Business Administration from Southern Connecticut State University and his JD and MBA from Suffolk University.
Marc Beer is the former Chief Executive Officer of Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR). Aegerion is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. Marc took the company public in October 2010. The Company’s first marketed product, JUXTAPID® (lomitapide) was approved by the US Food and Drug Administration in December 2012 for homozygous familial hypercholesterolemia. During his tenure, JUXTAPID obtained marketing approval in 36 countries. Additionally, Aegerion acquired its second product, MYALEPT® (metreleptin), approved in the US for generalized lipodystrophy, an ultra-rare disease.
Marc brings more than 25 years of development and commercialization experience in biotechnology, pharmaceuticals and diagnostics. In April 2000, Marc became the CEO of ViaCell, a biotechnology company specializing in the collection, preservation, and development of umbilical cord blood stem cells, and over a period of seven years led the company from its inception to a rapidly growing and robust commercial organization. Under Marc’s leadership, the company grew to more than 300 employees, went public in 2005 and was ultimately acquired in 2007 by PerkinElmer (NYSE: PKI).
Prior to ViaCell, Marc held various positions within Genzyme, most recently as Vice President of Global Marketing where he was responsible for the commercial launch of several products addressing rare disease populations on a global scale.
Prior to Genzyme, he held a variety of sales and marketing roles in the pharmaceutical and diagnostic divisions of Abbott Laboratories (NYSE: ABT). He also was a former member of the Mass Life Science Board of the Commonwealth of Massachusetts.
Marc serves on the Biotechnology Industry Organization (BIO) Emerging Companies Section Governing Board. He is chairman of the board of directors and chairman of the compensation committee of Good Start Genetics, Inc. and he is the chairman of the board, chairman of the compensation committee and member of the audit committee of Minerva Neurosciences Inc. (NASDAQ: NERV); Strategic Consultant to OvaScience; and a member of the Notre Dame Research and Commercialization Advisory Committee, Notre Dame Graduate Studies Research and Advisory Council and Miami University Business Advisory Council. He is also a member of the board and chair of the governance committee of the Joe Andruzzi Foundation. Marc holds a BS from Miami University (Ohio).
Carl L. Gordon is a founding Partner and Co-Head of Global Private Equity at OrbiMed. He was a senior biotechnology analyst at Mehta and Isaly from 1995 to 1997. He was at Fellow at The Rockefeller University from 1993 to 1995. Carl received a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology (1993) and a Bachelor of Arts degree from Harvard College (1987). Carl was included on the Forbes Midas List of top venture capital investors in 2014.
Thomas J. Flynn is a Managing Partner at SV Life Sciences Advisers, LLC, prior to which he held the positions of Partner and Venture Partner. In addition to Good Start Genetics, Tom currently sits on the boards of Health Essentials, Maestro Healthcare Technologies, Nordic Consulting Partners, Schweiger Dermatology, and Urgent Team Holdings. Before joining SV Life Sciences in 2011, Tom held various positions at Ferrer Freeman & Co., a health care-focused growth capital investor, including Partner and Chief Financial Officer. From 1996 to 2010, Tom served on numerous boards, including Aerocare Holdings, Inc., Amerita, Inc., a company owned by PharMerica Corporation (NYSE: PMC), GeneraMedix, Inc., Genova Diagnostics, Inc., Anthelio Healthcare Solutions, Inc. (formerly, PHNS, Inc.), as well as Physicians Dialysis, Inc., a company owned by DaVita Healthcare Partners, Inc. (NYSE: DVA), and Vitalize Consulting Solutions, Inc., a company acquired by Science Applications International Corporation (NYSE: SAIC), both co-investments with SVLS. Tom earned an MBA from Harvard University and a B.A. in Economics from College of the Holy Cross.
Dr. Gary J. Kurtzman is Managing Director at Safeguard Scientifics, Inc. (NYSE:SFE), which provides capital to technology-driven businesses in healthcare, financial services and digital media. Dr. Kurtzman is currently a board member for Safeguard’s partner companies Good Start Genetics, Medivo, meQuilibrium, Propeller Health, Syapse and Trice Medical (Chairman). With more than 30 years of experience as an entrepreneur, board member, financier and operator, Dr. Kurtzman has realized value for companies through a series of successful IPOs, M&A and turnaround transactions. Dr. Kurtzman’s previous experiences include leadership roles at BioAdvance, Pluvita Corporation, Genovo, Avigen, and Gilead Sciences. Dr. Kurtzman has authored more than 40 research articles, book chapters and reviews, and is credited as inventor on twelve issued U.S. patents. Presently, he serves on various academic and biomedical committees and boards, and is a lecturer in the Health Care Systems Department at the Wharton School at the University of Pennsylvania where he teaches entrepreneurship in life sciences. Dr. Kurtzman holds a bachelor’s degree from Stanford University and an M.D. from Washington University in St. Louis and did his postdoctoral training at the National Heart, Lung, and Blood Institute-NIH and Stanford University.
Mr. Robert J. Carpenter is Chairman of Hydra Biosciences Inc., a company that he helped found which conducts research in ion channels. Previously, Mr. Carpenter was Chief Executive Officer of Integrated Genetics, a public biopharmaceutical company which was acquired by Genzyme in 1989. Mr. Carpenter founded GelTex Pharmaceuticals which also went public and was acquired by Genzyme. Mr. Carpenter served on the Board of Genzyme from 1994 to 2011 most recently as Lead Director. Mr. Carpenter founded Boston Medical Investors in 1994 through which he started or invested in a number of healthcare companies. He currently serves as a Director of Moderna Therapeutics, Inc., SynapDx Corporation, Immuneering Inc, and Lysosomal Therapeutics, Inc. Mr. Carpenter received a B.S. from the United States Military Academy at West Point, an M.S. in Computer Science from Stanford University and an M.B.A. from Harvard Business School.
Charles F. Wagner, Jr, has served as one of our directors since April 2014. Mr. Wagner is currently Executive Vice President and Chief Financial Officer of Ortho Clinical Diagnostics, a global in vitro diagnostics leader serving the clinical lab and transfusion medicine communities. From July 2012 to June 2015, he served as Executive Vice President, Finance & Administration and Chief Financial Officer of Bruker Corporation (NASDAQ: BRKR), or Bruker, a global leader in analytical instrumentation and related solutions for life science, material science and applied markets. From November 2010 to March 2012, Mr. Wagner served as Executive Vice President, Finance & Administration and Chief Financial Officer of Progress Software Corporation (NASDAQ: PRGS), a provider of enterprise software located in Bedford, Massachusetts. Mr. Wagner served as Vice President and Chief Financial Officer of Millipore Corporation, or Millipore (NYSE: MIL), a global provider of products and services in the life science tools market, from 2007 until July 2010, when Millipore was acquired by Merck KGaA. Mr. Wagner successfully managed all financial and operational aspects of the sale of Millipore to Merck KGaA, a transaction valued at $7 billion. Prior to his employment at Bruker, Mr. Wagner served on the board of directors and as a member of the audit committee at Bruker from August 2010 through June 2012. Additionally, from August 2010 to March 2013, Mr. Wagner served as a director of Bruker Energy & Supercon Technologies, Inc., a subsidiary of Bruker, where he was a member of the audit committee. Mr. Wagner received an M.B.A. from Harvard University Graduate School of Business Administration and a B.S. from Boston College. We believe that Mr. Wagner’s qualification to sit on our board of directors include his broad management, financial and operational experience within the life sciences industry, including his current position as Chief Financial Officer of a global in vitro diagnostics company.
Paris Wallace currently serves as President and CEO of Ovuline. Ovuline is a consumer health company that uses machine learning, big data, wearable devices and clinical guidelines to help women conceive naturally and have healthy pregnancies. Paris is also the Co-President of the Harvard Business School Alumni Angels of Boston & New England, an angel investment group comprised of Harvard graduates that focuses on providing growth capital to seed and growth stage companies throughout New England.
Before Ovuline, Paris co-founded Good Start Genetics. Good Start Genetics is now one of the largest carrier screening companies in the US. Prior to Good Start Paris worked in the asset management division at Goldman Sachs and as a consultant for A.T. Kearney. Paris is a mentor at Techstars Boston. He enjoys mentoring and advising young companies and has lectured on entrepreneurship at Harvard Business School, MIT Sloan, Amherst College and the Wharton School at University of Pennsylvania.
Paris holds a bachelor’s degree from Amherst College, and an M.B.A. and M.P.A from Harvard University, where he was a Reynolds Fellow.